

1 **A Health Economic Evaluation for Implementing an Extended Half-life Monoclonal**
2 **Antibody for All Infants vs. Standard Care for Respiratory Virus Syncytial Prophylaxis in**
3 **Canada**

4
5 Thomas Shin MA, MPH^{1,2}, Jason KH Lee MSc Mbiotech, PhD (Candidate)^{1,3,a}, Alexia Kieffer
6 MSc, MPH, PhD⁴, Michael Greenberg MD, MPH⁴, Jianhong Wu PhD²

7
8 ¹Sanofi, 1755 Steeles Ave W, North York, Ontario, Canada M2R 3T4

9 ²York University, Department of Mathematics and Statistics N520 Ross, 4700 Keele Street,
10 Toronto, Ontario, Canada M3J 1P3

11 ³Leslie Dan School of Pharmacy, University of Toronto, 144 College St, Toronto, Ontario,
12 Canada M5S 3M2

13 ⁴Sanofi, Lyon, France

14
15 **Corresponding author:** thomas.shin@sanofi.com

16 ^aJason KH Lee is a co-first author

17
18
19 **Abstract**

20 Respiratory syncytial virus (RSV) is a highly infectious virus, and infants and young children are
21 particularly vulnerable to its progression to severe lower respiratory tract illness (LRTI).
22 Nirsevimab, an extended half-life monoclonal antibody, was recently approved in Canada as a
23 passive immunization intervention for the prevention of RSV LRTI. A static decision tree model
24 was utilized to determine the cost-effectiveness of nirsevimab in Canadian infants compared to
25 current standard of care (palivizumab for infants born preterm, and with specific chronic
26 conditions) and generate an optimal price per dose (PPD) at accepted willingness-to-pay (WTP)
27 thresholds. Various health outcomes (including hospitalization, ICU, and mechanical ventilation)
28 and healthcare costs were calculated over one RSV season, with any necessary follow-up
29 prophylaxis in the second season for three infant categories (palivizumab-eligible, preterm, and
30 term). All health-related parameters and costs were tailored to the Canadian environment.
31 Compared to scenarios where only at-risk segments of the infant population received nirsevimab,
32 the base case (administering nirsevimab to all infants in their first RSV season) was the most
33 cost-effective versus standard care: the PPD was \$692 at a \$40,000/QALY WTP threshold, using
34 average costing data assumptions across all scenarios. Compared to standard care, the base case
35 scenario could avoid 18,249 RSV-related health outcomes (reduction of 9.96%). Variations in
36 discount rate, distribution of monthly RSV infections, nirsevimab coverage rate for infants born
37 at term, and palivizumab cost had the most significant model impact. Passive immunization of all
38 infants with nirsevimab can significantly reduce RSV-related health and economic burden across
39 Canada.

40 **Keywords:** respiratory syncytial virus (RSV), nirsevimab, infants, Canada, health economics,
41 passive immunizations

42 **Introduction**

43 Respiratory syncytial virus (RSV) is a highly infectious and prevalent viral pathogen with
44 activity that follows an annual seasonal pattern.^{1,2} Afflicting individuals of all ages, RSV is
45 transmitted via respiratory droplets and exhibits a typical presentation of mild upper respiratory
46 tract symptoms such as sneezing, coughing and runny nose that resolve in 1-2 weeks.³ However,
47 subpopulations such as infants and young children are particularly vulnerable to more severe
48 illness with RSV,⁴ presenting as acute lower respiratory tract infection (LRTI), most commonly
49 bronchiolitis and pneumonia. In Canada, RSV is the leading cause of hospitalization in children
50 four years and younger,⁵ and 80% of these children were born at term with no underlying health
51 conditions.⁶ While RSV-associated death rates are highest in infants who were born premature,
52 the mortality burden is greatest in full-term infants given their proportionately large population.⁷
53 For children who recover from RSV, early infection may also have long-lasting health
54 consequences, as indicated by associations with recurrent wheezing and pediatric asthma.⁸
55 Infants are at the highest risk for severe manifestations of this virus during their first RSV
56 season,⁹ and nearly all children will be infected by two years of age;¹⁰ this high prevalence,
57 combined with the potential severity and long-term impact of RSV, signifies a tremendous unmet
58 medical need to protect infants from this infection.

59 RSV-related prophylaxis among infants represents a promising tool for reducing the significant
60 health and economic burden of RSV in Canada. However, until recently, palivizumab, a
61 monoclonal antibody, was the sole product available for RSV prevention in children and only
62 indicated for infants meeting stringent criteria encompassing early gestational age and the
63 presence of specific chronic conditions.¹¹ In order to protect all infants from severe RSV disease,
64 an extended half-life humanized monoclonal antibody with neutralizing activity was developed.

65 Nirsevimab acts as a viral inhibitor by binding to the fusion protein on the surface of the RSV
66 virus.¹² Two clinical trials have demonstrated a statistically significant reduction in the incidence
67 of medically-attended (MA) RSV LRTI after nirsevimab administration compared to placebo in
68 preterm infants born during or entering their first RSV season, term and late preterm infants, and
69 in children up to 24 months of age who remain vulnerable to severe RSV disease through their
70 second RSV season due to being preterm or having chronic lung disease of prematurity or
71 congenital heart disease.¹³⁻¹⁵ In Canada, nirsevimab is currently indicated for the prevention of
72 LRTI in neonates and infants during their first RSV season and in children up to 24 months at
73 high-risk for severe RSV disease in their second RSV season.¹⁶ In the US, the Advisory
74 Committee on Immunization Practices (ACIP) recently provided a unanimous recommendation
75 for the administration of nirsevimab to all infants aged <8 months born during or entering their
76 first RSV season and for those 8-19 months at increased risk for severe RSV entering their
77 second RSV season.¹⁷ Given the severity and seasonality of RSV, it is important to understand
78 the cost and clinical impact of different implementation scenarios within the pediatric population
79 to ensure optimal and cost-effective protection. We implemented an externally validated
80 economic model comparing nirsevimab to the standard of care in Canada, utilizing various
81 willingness-to-pay (WTP) thresholds to determine the optimized price per dose for nirsevimab in
82 Canada for the reduction of medically-attended RSV infections and hospitalizations from a
83 societal perspective.

84 **Methods**

85 *Overview*

86 A static decision tree model followed a cohort of Canadian newborn infants segmented into three
87 categories based on risks for severe RSV: 1) preterm infants (<37 weeks gestational age [WGA])

88 eligible to receive palivizumab (“palivizumab-eligible”); 2) healthy preterm infants (<37 weeks
89 wGA); and 3) infants born at term (≥ 37 wGA). The definition of palivizumab-eligible infants
90 was based on criteria reported in the Canadian literature.¹⁸ Based on Canadian RSV surveillance
91 data, the RSV season was assumed to increase in activity from November to the end of the
92 following March.¹⁶ In the base case scenario, all infants born outside and inside the RSV season
93 were administered nirsevimab during their first RSV season in the treatment arm (those born
94 prior to the season received nirsevimab at the season’s start), with a select proportion of preterm
95 infants receiving follow-up treatment in the subsequent season. Therefore, the newborn cohort
96 was followed for two RSV seasons. The comparator arm was the standard of care (i.e.,
97 palivizumab), which only applied to a small proportion of infants meeting Canada’s strict
98 eligibility criteria.¹⁸ The model simulated the patient trajectory of RSV infection with health
99 outcomes, including RSV-related hospitalization, intensive care admission (ICU), mechanical
100 ventilation (MV), emergency and general practitioner admissions (ER, GP), and RSV-related
101 mortality. Direct and indirect costs associated with MA RSV LRTI were integrated into the
102 model, which assumed the societal perspective. All mortality-related costs and outcomes were
103 discounted at a rate of 1.5%, as recommended by national guidelines.¹⁹

104 The model integrated the following elements: population data (segmented by palivizumab-
105 eligible, preterm, and term infants), seasonality of RSV, coverage and adherence rates, clinical
106 profiles of therapies, RSV-related health outcomes (e.g., hospitalization, ICU, MV), outcome-
107 related utility values, and outcome specific costs. In order to capture the seasonality of RSV, the
108 implementation scenarios of nirsevimab by subgroup (e.g., born in-season, born out-of-season,
109 palivizumab-eligible, preterm, term), and an accurate assessment of price per dose, the economic
110 model required granular (monthly) data inputs. These monthly inputs included population birth,

111 probability of RSV infection, and RSV-related health outcomes. A comprehensive list of
112 parameters utilized in the model is presented in Table 1.

113 *Health Outcome Parameters*

114 The grey and peer-reviewed literature was systematically reviewed to identify ongoing and
115 completed health economic, clinical, and epidemiological studies related to RSV and
116 palivizumab. Population-based data, with the subgroups of interest and the monthly probability
117 of infection, were derived from national statistics and surveillance data.^{20,21} All inputs for
118 nirsevimab were derived from Phase 2b and Phase 3 studies, while the grey literature provided
119 insights into palivizumab’s cost and clinical profile.^{13-15,18,22} Where possible, only up-to-date
120 Canadian inputs were utilized to populate the model; however, in the complete absence of such
121 data, US-specific inputs were adopted (e.g. data related to RSV-specific QALY loss and
122 mortality outcomes). Data associated with RSV-related inpatient hospitalization, ICU
123 admissions, and patients requiring MV were generated per infant subgroup, using a combination
124 of average Canadian inputs and distributions of monthly US data (0-36 months age of infection).
125 Informed by expert opinion, we assumed US-based monthly distributions as an acceptable proxy
126 for generating “Canadianized” values per subgroup. Figure 1 illustrates the distributional
127 conversion formula for generating Canadian values, utilizing an average of Canadian-specific
128 inputs (see Table 2). Furthermore, for ER and primary care admissions, US-based monthly
129 percentages (0-36 months age of infection) were utilized in the absence of monthly data for
130 Canada.²³

131 RSV-related input parameters are provided in Tables 1 and 2.

132

133 *Economic Parameters*

134 All costs are outlined in Table 3 with inflation adjustments using the Canadian Consumer Price
135 Index (CPI), and adjusted to 2023 Canadian dollars. Although the model adopts a national scope,
136 most RSV-specific costs within the past five years were from Ontario, Alberta, and Quebec-
137 specific peer-reviewed sources due to availability.²⁴⁻²⁷ Furthermore, grey literature on the cost-
138 effectiveness and recommended use of palivizumab provided overall support for model
139 parametrization.^{18,22} Direct healthcare costs per RSV-related health outcome required the
140 establishment of a costing matrix with an average cost per health outcome by subgroup (i.e.
141 palivizumab-eligible, preterm, and term infants). ER, GP, and direct non-medical costs per
142 hospitalization (i.e., travel, meals, childcare, and out-of-pocket expenses attributed to RSV-
143 related hospitalization) were assumed to be uniform across subgroups and remained constant
144 regardless of scenario analysis. In contrast, inpatient hospitalization, ICU, and MV costs required
145 calculations based on different sources. The primary costing scenario (S₀) was used for base case
146 modelling; intended as a representation of a broader Canadian costing perspective, it was
147 generated by averaging all scenarios (S1a, S1b, S2, S3, and S4, as described below). For the
148 majority of the scenarios, the distribution of costs per subgroup were derived from McLaurin et
149 al.²⁸ For Scenario S1a and S1b, the recent Canadian literature from Rafferty et al. provided
150 average RSV-attributable lab-confirmed hospitalization costs within 30 days and 365 days post-
151 diagnosis by age group.²⁷ Utilizing matrix algebra, the case-weighted cost for infants <1 year
152 was applied to the distribution from McLaurin et al. to establish values within the costing matrix
153 S1a and S1b.²⁸ In Scenario 2 (S2), cost outcomes were based on Thampi et al. (2021), with cost
154 differentials between palivizumab-eligible, preterm, and term infants but not across the different
155 health outcomes (e.g., inpatient hospitalization, ICU, MV).²⁶ Scenario 3 (S3), derived inputs

156 from Buchan et al. (2019), and applied a similar costing approach as S2.²⁷ Scenario 4 (S4)
157 utilized the detailed costs from Papenberg et al. (2020), where direct and indirect RSV-related
158 costs were sourced from multiple Quebec-specific resources (e.g. the Quebec government’s
159 health insurance board Régie de l’assurance maladie du Québec [RAMQ], McGill University
160 Health Centre, etc.).²⁵

161 *Costing Scenarios*

162 The price per dose optimization scenarios were based on four WTP thresholds (incremental cost
163 per quality-adjusted life years [QALY]) of \$40,000, \$50,000, \$70,000, and \$100,000 per QALY,
164 which represent the commonly accepted thresholds by North American health technology
165 assessment (HTA) bodies, such as Canada’s Drug and Technology Agency (CADTH), Institut
166 national d’excellence en santé en services sociaux (INESSS), National Advisory Committee of
167 Immunization (NACI), and Institute for Clinical and Economic Review (ICER).^{19,29-31} The
168 primary costing scenario (S₀) attempted to represent a pan-Canadian perspective by averaging
169 the costing matrices of all scenarios. Scenarios S1a and S1b utilized the average RSV-
170 attributable lab-confirmed hospitalization costs within 30 days and 365 days (for those <1 year of
171 age) to populate the costing matrix provided by McLaurin et al. Two additional scenarios (S2,
172 S3) derived inputs from Ontario-specific sources with no assumptions regarding underlying cost
173 distributions.^{26,27} In S2, costs were derived from Ontario’s RSV-focused population-based match
174 cohort study.²⁶ Costs for inpatient hospitalization, ICU, and MV among the preterm infants
175 eligible for palivizumab were calculated based on the weighted mean adjusted costs for
176 congenital heart disease (CHD), hemodynamically significant CHD, congenital lung disease
177 (CLD), and birth between 22 and 28 wGA. Similar calculations were applied to preterm infants
178 (29-35 wGA) and term infants (36-43 wGA or full-term with no comorbidities). Relative to the

179 S₀, S_{1a}, S_{1b}, and S₂, the Ontario-based costing data in S₃ was less granular, providing two
180 average costs for young children ≤ 59 months with and without ≥ 1 comorbidity.²⁷ S₄ was based
181 on Quebec-specific data providing the granular hospitalization costs attributed to RSV (e.g.
182 pediatric unit, perinatal ICU, neonatal ICU, short-stay unit, ER) across a wide scope of cost
183 outcomes ranging from hospital stay, administration, procedural, specialist, hospital discharge,
184 outpatient resource use, productivity, and out-of-pocket auxiliary costs.²⁵

185 ***Implementation Scenarios***

186 For all costing scenarios (S₀, S_{1a}, S_{1b}, S₂, S₃, S₄), analyses were conducted to explore the price
187 per dose contingent on the scope of program implementation. The scope included four
188 implementation scenarios: 1) all infants (i.e. palivizumab-eligible, preterm, and term) born
189 within and outside of the RSV season (base case scenario); 2) palivizumab-eligible and preterm
190 infants born within and outside of the RSV season (with the exclusion of term infants); 3)
191 palivizumab-eligible and preterm infants born within and outside of the RSV season, and term
192 infants 0-3 months entering their first RSV season and term infants born during the RSV season;
193 and 4) palivizumab-eligible and preterm infants born within and outside of the RSV season and
194 term infants born during the RSV season.

195 ***Deterministic Sensitivity Analyses***

196 A univariate sensitivity analysis was conducted to understand which variables significantly
197 impacted the price per dose. The lower and upper bounds from the 95% confidence intervals (CI)
198 were used where available; alternatively, we utilized a variance of $\pm 20\%$.

199

200

201 **Results**

202 *Price Per Dose*

203 The price per dose of nirsevimab at the four WTP thresholds is presented in Table 4 for all
204 costing and implementation scenarios, including the base case, which was consistently the least
205 costly of the scenarios modelled. Using a WTP threshold of \$40,000 per QALY, immunizing all
206 infants born in and out of season would be cost-effective from a societal perspective at a PPD of
207 \$692 for the primary costing scenario (S₀) and ranged from \$634 to \$769 depending on the
208 source of costing input; at the highest WTP threshold of 100,000/QALY, the PPD increased to
209 \$894 (range: \$836 to \$971). Of all costing scenarios, S₃, which derived its costing input from an
210 Ontario-based RSV study that calculated costs for all children <59 months (stratified by presence
211 or absence of at least one comorbidity) rather than more granular age groups, consistently
212 yielded the lowest PPDs; the highest PPDs were generated by S_{1b}, a scenario that used the
213 average RSV-attributable lab-confirmed hospitalization costs within one year.

214 Of all implementation scenarios, immunizing only palivizumab-eligible children and those
215 preterm and born in and out of season generated the highest PPD for nirsevimab: \$3,767 at a
216 WTP threshold of \$40,000/QALY and \$4,126 at the highest threshold (i.e., \$100,000/QALY).

217 *Clinical and Cost Impact*

218 A comparison was conducted of the clinical and cost impact of administering nirsevimab to all
219 infants (base case scenario) relative to the standard of care. Compared to current practice, the
220 base case implementation strategy could avoid 18,249 RSV-related health outcomes (9.96%),
221 including three inpatient deaths and 812 inpatient hospitalizations (Table 5). Use of the base case
222 strategy also could avoid 4,071 ER visits, a reduction of 10.2%. The reduction of health

223 outcomes is associated with a potential cost-savings of \$26,324,578 (range of \$19.7M to \$34.9M
224 for the additional scenarios utilizing short-term and long-term RSV-attributed hospitalization
225 costs, respectively), of which 63.6% could be attributed to a reduction in direct costs, primarily
226 derived from avoidance of hospitalization and ICU stays. The majority of both total outcomes
227 avoided (99.7%), and resultant cost-savings (97.5%) are attributed to providing nirsevimab as
228 RSV prophylaxis to otherwise healthy full-term and preterm children who are not eligible for
229 palivizumab.

230 *Deterministic Sensitivity Analysis*

231 The results of the univariate sensitivity analysis for the base case scenario (nirsevimab provided
232 to all infants within and outside RSV season) at the \$40,000 WTP threshold are displayed in the
233 Tornado diagram in Figure 4. The factors resulting in the most variation in PPD were the
234 discount rate, the variance of distribution of monthly RSV, the coverage rate of nirsevimab for
235 infants born at term, and the cost of palivizumab. [Figure 4 here]

236 **Discussion**

237 The approval of nirsevimab as RSV prophylaxis in Canada represents a valuable source of
238 protection for infants and young children against a disease that is associated with significant
239 morbidity and healthcare resource utilization. Our study demonstrates that compared to scenarios
240 where only specific segments of the infant population receive nirsevimab, administering
241 nirsevimab to all infants during their first RSV season was the most cost-effective scenario
242 compared to standard care, yielding a PPD of \$692 at a \$40,000/QALY willingness-to-pay
243 threshold. In comparison to current standard care, the base case could avoid 18,249 RSV-related
244 health outcomes (reduction of 9.96%) for a cost savings of \$26,324,578. Our model estimates

245 that passive immunization of all infants with nirsevimab could prevent approximately 812
246 hospitalizations. The largest RSV-related hospitalization burden occurs in term and preterm
247 children who are otherwise healthy and, therefore, not eligible for palivizumab. While premature
248 infants are at the highest risk for severe RSV-related outcomes requiring hospitalization,^{32,33} they
249 comprise only a small percentage of the birth cohort (and therefore a smaller overall health and
250 cost burden) compared to healthy term and preterm infants.

251 Our sensitivity analysis revealed that increasing the discount rate, the variations in monthly
252 disease incidence and the cost of palivizumab, and decreasing nirsevimab coverage rate (our
253 model assumed a rate of 30%) would each result in a higher PPD for nirsevimab. Immunization
254 programs are often sensitive to discounting since benefits may not be realized immediately, as
255 with conventional curative therapies.³⁴ Instead, there are often time delays between the time of
256 dose administration and when disease is averted, and discount rates become more impactful. We
257 based our coverage rate assumption on influenza vaccine uptake in the infant population;³⁵ given
258 the potential risk and severity of influenza as a respiratory infection, particularly in infants, we
259 deemed this an appropriate proxy. As nirsevimab becomes routinely administered in the United
260 States and elsewhere as part of RSV prophylaxis, a more informed coverage rate assumption will
261 be possible.

262 Unlike many other diseases, the seasonality of RSV translates to a substantial variation in risk of
263 infection from month to month. Previous studies have demonstrated that RSV-associated
264 hospitalizations and healthcare costs were the highest for children born between September and
265 February, who, therefore, had early exposure to the virus, with rates peaking in December and
266 declining into April and after.³⁶⁻³⁹ Due to this monthly change in viral risk combined with
267 granularity in palivizumab and nirsevimab's current indications for use in Canada, we strived to

268 utilize monthly data inputs from Canada in our model. Given the lack of such data and the
269 common seasonality of RSV and similar incidence in infants in Canada and the United
270 States,^{40,41} we opted to extrapolate US-based health outcomes and cost inputs and modify them
271 using average Canadian values. Incorporating monthly data inputs was deemed critical to the
272 ability of our model to estimate the clinical and cost impact of nirsevimab vs. standard care.
273 Our costing scenarios were informed by recent Canadian studies, which used different models
274 and sources of data to evaluate the healthcare costs and burden of RSV in infants and young
275 children²⁴⁻²⁷ Though the model by Rafferty estimates costs utilizing data from Alberta, it also
276 incorporates national RSV positivity data to estimate the incidence and may be more likely to
277 have widespread applicability across Canada than if a province-specific rate was used. Rafferty's
278 study was also unique in that it calculated outcomes at 30 days and 365 days post-infection, a
279 valuable stratification given the progression of RSV illness and the changing need for healthcare
280 resources. Thampi et al.'s model considered children under 24 months and examined direct
281 medical costs per hospitalized child with RSV over a 12-month period. While Buchan et al.'s
282 model did the same for children under five years of age in an earlier publication, Thampi et al.
283 included attributable costs associated with ER visits, inpatient hospitalization, same-day
284 surgeries, inpatient rehabilitation, physician and outpatient diagnostic and laboratory services.
285 The model by Papenburg et al. utilized Quebec data for RSV and LRTI hospitalizations among
286 infants younger than six months at the start of, or born during the RSV season, assessing costs up
287 to 30 days discharge. Given that these studies vary considerably in model inputs and age group
288 granularity, and utilize data from different provinces, our base case analysis utilized an average
289 of these costing scenarios to capture a pan-Canadian perspective.

290 We calculated the optimal PPD of nirsevimab at various widely accepted WTP thresholds, as
291 Canada does not adhere to one official cost-effectiveness threshold to inform national and
292 provincial recommendations and decisions. At a \$40,000/QALY threshold, our model generated
293 a base case price per dose of \$692, with a range of \$634 to \$769, depending on the source of
294 costing input. Costing models from the United States Centers for Disease Control (CDC) and
295 Prevention's Advisory Committee on Immunization Practices (ACIP) have utilized a list price of
296 \$445 USD (approximately \$600 CAD) per dose of nirsevimab.⁴² The Sanofi US health economic
297 model for nirsevimab vs. standard care assumed a price of \$500 USD (approximately \$670
298 CAD),⁴² which is the approximate private market list price in the US.⁴³ The current public CDC
299 vaccine price list (per dose) indicates a \$395 USD (\$530 CAD) public price and a \$495 USD
300 (\$665 CAD) private price regardless of the dose concentration. A recently published Canadian
301 cost-effectiveness study established nirsevimab's maximum price per dose (PPD) to range
302 between \$575 and \$595 CAD based on a societal all-infant administration approach with
303 consideration for RSV-related mortality, differing efficacy profiles (i.e. sigmoidal versus
304 constant), 80%-100% product uptake, and a \$50,000 per QALY willingness-to-pay (WTP)
305 threshold.⁴⁴ The analysis findings demonstrated that the larger the target infant population for
306 nirsevimab administration, the greater the reduction in RSV burden; the maximum PPD may
307 have been conservative given that there was no standard of care comparator for any subgroup of
308 infants (i.e. palivizumab).⁴⁵ Therefore, our model's generated PPD for the base case scenario
309 seems well-aligned with current prices of nirsevimab from the literature, with additional PPDs,
310 which are higher in maximum price based on alternative implementation scenarios targeting
311 select at-risk segments of the infant population.

312 Our analysis has several strengths, including the use of a range of hospitalization costing data
313 and a costing matrix to incorporate hospitalization-related costs per level of RSV risk, the
314 assessment of various immunization scenarios, the stratification of the infant population by
315 gestational age at birth, and the inclusion of various medically-attended health outcomes and
316 mortality. Furthermore, our model attempted to capture the variability of RSV-related burden
317 and costs based upon the most up-to-date Canadian-specific economic literature. However, our
318 model has several limitations. As stated earlier, we assumed that Canadian RSV health-related
319 inputs would follow a US-based distribution; while this assumption was supported by the similar
320 incidence rates of RSV in both countries, differences in healthcare delivery, practice patterns and
321 healthcare-seeking behaviour may have led to variation that we did not consider. We also
322 assumed that healthcare costs would differ between subgroups and adjusted our model's
323 hospitalization-related inputs according to the costing matrix; using US data to inform the matrix
324 may have introduced differences in our model. However, Canadian literature suggests that
325 hospitalization length of stay, need for ICU stay, and use of mechanical ventilation vary
326 considerably based on wGA and underlying conditions, with the implication of significant
327 differences in cost between risk subgroups by province.²⁵ Based on our guidance from external
328 experts, we deemed that integrating this into our model would enhance its accuracy.
329 Additionally, our model assumed that infants with RSV infection would be immune for the rest
330 of the study period and did not account for re-infection; the impact is likely low, given that
331 previous studies report that re-infection is typically mild.¹⁰ Our model did not include the RSV-
332 related costs associated with long-term sequelae such as asthma, wheezing, otitis media, and
333 reduced pulmonary function incurred after hospitalization, which has been linked to RSV.⁴⁶

334 Our study demonstrates that a passive immunization strategy for all infants with nirsevimab
335 could be cost-effective at a WTP threshold of \$40,000/QALY, provided the nirsevimab PPD is
336 less than \$692. This implementation scenario could result in significant reductions in the health
337 and economic burden of RSV in Canada compared to the current standard of practice of
338 administering palivizumab to certain at-risk infants only.

339 **Acknowledgements**

340 Sanofi would like to acknowledge the input and feedback from various clinical and health
341 economic experts from multiple advisory boards across Canada for the refinement and
342 development of this costing model.

343 **Declaration of Interest Statement**

344 TS, JKHL, MG and AK are employees of Sanofi, the manufacturer of nirsevimab (jointly with
345 AstraZeneca). JW currently serves as the Sanofi Industrial Research Chair.

346 **Funding**

347 This work was supported by Sanofi and AstraZeneca.

348 **Author Contributions**

349 Study conception, design, analysis, interpretation and manuscript development were lead and
350 supported by TS, JKHL, MG and AK; JW provided expertise in methodology and model
351 validation. All authors reviewed and approved the final version of the manuscript and are
352 accountable for all aspects of the work.

353 **Data Availability**

354 Please contact the primary author for any inquiries pertaining to the model and input data.

355

356

357 **References**

- 358 1. Li Y, Wang X, Broberg EK, Campbell H, Nair H, European RSV Surveillance Network.
359 Seasonality of respiratory syncytial virus and its association with meteorological factors in 13
360 European countries, week 40 2010 to week 39 2019. *Euro Surveill.* 2022;27(16):2100619. doi:
361 10.2807/1560-7917.ES.2022.27.16.2100619.
- 362 2. Radhakrishnan D, Ouedraogo A, Shariff SZ, McNally JD, Benchimol EI, Clemens KK. The
363 association between climate, geography and respiratory syncytial virus hospitalizations among
364 children in Ontario, Canada: a population-based study. *BMC Infect Dis.* 2020;20(1):157. doi:
365 10.1186/s12879-020-4882-6.
- 366 3. La Vla WV, Marks MI, Stutman HR. Respiratory syncytial virus puzzle: clinical features,
367 pathophysiology, treatment, and prevention. *J Pediatr.* 1992;121(4):503-10. doi: 10.1016/s0022-
368 3476(05)81135-7.
- 369 4. Chatterjee A, Mavunda K, Krilov LR. Current State of Respiratory syncytial virus disease and
370 management. *Infect Dis Ther.* 2021;10(Suppl 1):5–16. doi: 10.1007/s40121-020-00387-2.
- 371 5. Schanzer DL, Saboui M, Lee L, Nwosu A, Bancej C. Burden of influenza, respiratory
372 syncytial virus, and other respiratory viruses and the completeness of respiratory viral
373 identification among respiratory inpatients, Canada, 2003-2014. *Influenza Other Respir Viruses.*
374 2018;12(1):113-121. doi: 10.1111/irv.12497.
- 375 6. Pisesky A, Benchimol EI, Wong CA, Hui C, Crowe M, Belair M-A, Pojsupap S, Karnauchow
376 T, O’Hearn K, Yasseen AS, et al. Incidence of hospitalization for respiratory syncytial virus
377 infection amongst children in Ontario, Canada: a population-based study using validated health
378 administrative data. *PLoS ONE.* 2016;11(3): e0150416. doi: 10.1371/journal.pone.0150416.

- 379 7. Reichert H, Suh M, Jiang X, Movva N, Bylsma LC, Fryzek JP, Nelson CB. Mortality
380 associated with respiratory syncytial virus, bronchiolitis, and influenza among infants in the
381 United States: A birth cohort study from 1999 to 2018. *J Infect Dis.* 2022;226(Suppl 2):S246-
382 S254. doi: 10.1093/infdis/jiac127
- 383 8. Makrinioti H, Hasegawa K, Lakoumentas J, Xepapadaki P, Tsolia M, Castro-Rodriguez JA,
384 Feleszko W, Jartti T, Johnston SL, Bush A, Papaevangelou V, Camargo CA Jr, Papadopoulos
385 NG. The role of respiratory syncytial virus- and rhinovirus-induced bronchiolitis in recurrent
386 wheeze and asthma-A systematic review and meta-analysis. *Pediatr Allergy Immunol.*
387 2022;33(3):e13741. doi: 10.1111/pai.13741.
- 388 9. Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells
389 E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute
390 lower respiratory infections due to respiratory syncytial virus in young children in 2015: a
391 systematic review and modelling study. *Lancet.* 2017;390(10098):946–58. doi: 10.1016/S0140-
392 6736(17)30938-8.
- 393 10. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with
394 respiratory syncytial virus. *Am J Dis Child.* 1986;140(6):543-6. doi:
395 10.1001/archpedi.1986.02140200053026.
- 396 11. Resch B. Product review on the monoclonal antibody palivizumab for prevention of
397 respiratory syncytial virus infection. *Hum Vaccin Immunother.* 2017;13(9):2138-2149. doi:
398 10.1080/21645515.2017.1337614.
- 399 12. AstraZeneca Canada Inc, Sanofi Pasteur Ltd. Beyfortus (nirsevimab injection): solution for
400 injection, 100 mg/mL, intramuscular use, 50 mg single-use, pre-filled syringe, 100 mg single-

401 use, pre-filled syringe [product monograph]. Mississauga (ON): AstraZeneca Canada Inc.; 2022
402 Nov 1.

403 13. Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ,
404 Brooks D, Grenham A, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term
405 infants. *N Engl J Med.* 2022;386(9):837-846. doi: 10.1056/NEJMoa2110275.

406 14. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Esser MT, Khan
407 AA, Dubovsky F, Villafana T, et al. Single-dose nirsevimab for prevention of RSV in preterm
408 infants. *New Engl J Med.* 2020;383(5):415-25. doi: 10.1056/NEJMoa1913556.

409 15. Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, Hammitt LL,
410 Llapur CJ, Novoa JM, Llorens XS, et al. Nirsevimab for prevention of RSV in term and late-
411 preterm infants. *N Engl J Med.* 2023; 388(16):1533-1534. doi: 10.1056/NEJMc2214773.

412 16. Government of Canada. Respiratory syncytial virus: Canadian immunization guide.
413 [Accessed 2023 09 01] [https://www.canada.ca/en/public-health/services/publications/healthy-](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html)
414 [living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html](https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html)

415 17. Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sanchez PJ, Kotton CN,
416 Mahon BE, Meyer S, Long SS, et al. Use of Nirsevimab for the Prevention of Respiratory
417 Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory
418 Committee on Immunization Practices — United States, 2023. *MMWR Morbidity and Mortality*
419 *weekly report.* 2023;72:920-5.

420 18. National Advisory Committee on Immunization. An Advisory Committee Statement (ACS)
421 National Advisory Committee on Immunization (NACI) - Recommended use of palivizumab to
422 reduce complications of respiratory syncytial virus infection in infants. In: Public Health Agency
423 of Canada (PHAC), editor. Ottawa, Canada,2022.

- 424 19. Public Health Agency of Canada (PHAC). Guidelines for the economic evaluation of
425 vaccination programs in Canada. In: National Advisory Committee on Immunization, editor. 1
426 ed2023.
- 427 20. Statistics Canada. Table 13-10-0425-01 Live births by weeks of gestation 2022 [Accessed
428 2023 08 30] <https://www150.statcan.gc.ca/t1/tb11/en/tv.action?pid=1310042501>
- 429 21. Public Health Agency of Canada (PHAC). Respiratory Virus Detections in Canada 2023
430 [Accessed 2023 08 30] [https://www.canada.ca/en/public-health/services/surveillance/respiratory-](https://www.canada.ca/en/public-health/services/surveillance/respiratory-virus-detections-canada.html)
431 [virus-detections-canada.html](https://www.canada.ca/en/public-health/services/surveillance/respiratory-virus-detections-canada.html)
- 432 22. National Advisory Committee on Immunization. Cost-effectiveness of palivizumab
433 prophylaxis for respiratory syncytial virus (RSV): a systematic review. In: (PHAC) PHAoC,
434 editor. Ottawa 2023.
- 435 23. Lively JY, Curns AT, Weinberg GA, Edwards KM, Staat MA, Prill MM, Gerber SI, Langley
436 GE. Respiratory syncytial virus-associated outpatient visits among children younger than 24
437 months. *J Pediatric Infect Dis Soc.* 2019;8(3):284-6. doi: 10.1093/jpids/piz011.
- 438 24. Rafferty E, Paulden M, Buchan SA, Robinson JL, Bettinger JA, Kumar M, Swenson LW,
439 MacDonald SE, Canadian Immunization Research Network (CIRN) investigators. Evaluating the
440 individual healthcare costs and burden of disease associated with RSV across age groups.
441 *PharmacoEconomics.* 2022;40(6):633-645. doi: 10.1007/s40273-022-01142-w.
- 442 25. Papenburg J, Saleem M, Teselink J, Li A, Caouette G, Massé É, Lanctot KL. Cost-analysis of
443 withdrawing immunoprophylaxis for respiratory syncytial virus in infants born at 33-35 weeks
444 gestational age in Quebec: a multicenter retrospective study. *Ped Infect Dis J.* 2020;39(8):694-9.
445 doi: 10.1097/INF.0000000000002719.

- 446 26. Thampi N, Knight BD, Thavorn K, Webster RJ, Lanctot K, Hawken S, McNally JD. Health
447 care costs of hospitalization of young children for respiratory syncytial virus infections: a
448 population-based matched cohort study. *CMAJ Open*. 2021;9(4):E948-e56. doi:
449 10.9778/cmajo.20200219.
- 450 27. Buchan SA, Chung H, Karnauchow T, McNally JD, Campitelli MA, Gubbay JB, Katz K,
451 McGeer AJ, Richardson DC, Simor A, et al. Characteristics and outcomes of young children
452 hospitalized with laboratory-confirmed influenza or respiratory syncytial virus in Ontario,
453 Canada, 2009-2014. *Ped Infect Dis J*. 2019;38(4):362-9. doi: 10.1097/INF.0000000000002164.
- 454 28. McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus
455 hospitalization outcomes and costs of full-term and preterm infants. *Journal of Perinatology:*
456 *official journal of the California Perinatal Association*. 2016;36(11):990-6. doi:
457 10.1038/jp.2016.113.
- 458 29. CADTH. *Methods and Guidelines: Guidelines for the Economic Evaluation of Health*
459 *Technologies: Canada (4th Edition) 2017* [Accessed 2023 08 28]
460 [https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health](https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf)
461 [technologies_canada_4th_ed.pdf](https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf).
- 462 30. Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining
463 the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries
464 based on growth in life expectancy and health expenditures. *The Lancet Global Health*.
465 2023;11(6):e833-e42. doi: 10.1016/S2214-109X(23)00162-6.
- 466 31. Institute for Clinical and Economic Review (ICER). *2020-2023 Value Assessment*
467 *Framework*. 2020.

- 468 32. Lanari M, Anderson EJ, Sheridan-Pereira M, Carbonell-Estrany X, Paes B, Rodgers-Gray
469 BS, Fullarton JR, Grubb E, Blanken M. Burden of respiratory syncytial virus hospitalisation
470 among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis
471 of seven studies. *Epidemiol Infect.* 2020;148:e170. doi: 10.1017/S0950268820001661.
- 472 33. Figueras-Aloy J, Manzoni P, Paes B, Simoes EA, Bont L, Checchia PA, Fauroux B,
473 Carbonell-Estrany X. Defining the risk and associated morbidity and mortality of severe
474 respiratory syncytial virus infection among preterm infants without chronic lung disease or
475 congenital heart disease. *Infect Dis Ther.* 2016;5(4):417-452. doi: 10.1007/s40121-016-0130-1.
- 476 34. World Health Organization: Immunization Vaccines and Biologicals. (2019). WHO guide for
477 standardization of economic evaluations of immunization programmes.[Accessed 2023 09
478 01] <https://apps.who.int/iris/bitstream/handle/10665/329389/WHO-IVB-19.10-eng.pdf>
- 479 35. Statistics Canada. Table 13-10-0096-25 Influenza immunization in the past 12 months, by
480 age group.
- 481 36. Demont C, Petrica N, Bardoulat I, Duret S, Watier L, Chosidow A, Lorrot M, Kieffer A,
482 Lemaitre M. Economic and disease burden of RSV-associated hospitalizations in young children
483 in France, from 2010 through 2018. *BMC Infect Dis.* 2021;21(1):730. doi: 10.1186/s12879-021-
484 06399-8.
- 485 37. Kramer R, Duclos A, Lina B, Casalegno J-S. Cost and burden of RSV-related hospitalisation
486 from 2012 to 2017 in the first year of life in Lyon, France. *Vaccine.* 2018;36(45):6591–6593.
487 doi: 10.1016/j.vaccine.2018.09.029.
- 488 38. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodríguez-Tenreiro C, Sly P, Ramilo
489 O, Mejías A, Baraldi E, Papadopoulos NG, Nair H, Nunes MC, et al. Respiratory syncytial virus
490 seasonality: a global overview. *J Infect Dis.* 2018;217(9):1356–1364. doi: 10.1093/infdis/jiy056.

- 491 39. Hawkes MT, Lee BE, Kanji JN, Zelyas N, Wong K, Barton M, Mukhi S, Robinson JL.
492 Seasonality of respiratory viruses at Northern latitudes. *JAMA Netw Open*. 2021;4(9):e2124650.
493 doi:10.1001/jamanetworkopen.2021.24650.
- 494 40. McLaughlin JM, Khan F, Schmitt HJ, Agosti Y, Jodar L, Simões EAF, Swerdlow DL.
495 Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic
496 review and meta-analysis. *J Infect Dis*. 2022;15;225(6):1100-1111. doi: 10.1093/infdis/jiaa752.
- 497 41. Buchan SA, Chung H, To T, Daneman N, Guttman A, Kwong JC, Murti M, Aryal G,
498 Campigotto A, Chakraborty P, et al. Estimating the incidence of first RSV hospitalization in
499 children born in Ontario, Canada. *J Pediatric Infect Dis Soc*. 2023;12(7):421-430. doi:
500 10.1093/jpids/piad045.
- 501 42. National Center for Immunization and Respiratory Diseases. Economics of preventing
502 respiratory syncytial virus lower respiratory tract infections (RSV LRTI) among US infants with
503 nirsevimab - a summary report comparing models from: Sanofi AND University of Michigan
504 and CDC. [Accessed 2023 08 31]
505 [https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/rsv-](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/rsv-pediatric-03-sanchez-508.pdf)
506 [pediatric-03-sanchez-508.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/rsv-pediatric-03-sanchez-508.pdf).
- 507 43. Centers for Disease Control and Prevention. CDC Vaccine Price List. [Accessed 2024 03 25]
508 [https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-](https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html)
509 [list/index.html](https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html).
- 510 44. Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM. Cost-
511 effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of
512 Respiratory Syncytial Virus disease among infants in Canada: a simulation study. *The Lancet*
513 *Regional Health - Americas*. 2023;28:100629.

- 514 45. Li X, Bilcke J, Beutels P. Pricey or priceless: cost-effectiveness of respiratory syncytial virus
515 (RSV) prevention in infants. *Lancet Reg Health Am.* 2023;29:100657. doi:
516 10.1016/j.lana.2023.100657.
- 517 46. Respiratory syncytial virus. In: Kimberlin DW, editor. *Red Book: 2018 Report of the*
518 *Committee on Infectious Diseases.* 31st ed. Elk Grove Village, IL: American Academy of
519 *Pediatrics.* 2018:682–692.
- 520 47. IQVIA. Synagis sales by SKU (50MG and 100MG) 2020.
- 521 48. Drysdale SB. A Phase 3 randomized open-label study of nirsevimab (versus no intervention)
522 in preventing hospitalizations due to respiratory syncytial virus (RSV) in infants (HARMONIE)
523 [Oral presentation]. *ESPID 2023*; Lisbon, Portugal 2023.
- 524 49. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Vrca VB, Barsic B. Monoclonal
525 antibody for reducing the risk of respiratory syncytial virus infection in children. *Cochrane*
526 *Database Syst Rev.* 2013;(4): CD006602. doi: 10.1002/14651858.CD006602.pub4.
- 527 50. Food and Drug Administration (FDA). Highlights of prescribing information: BEYFORTUS
528 (Product Monograph) 2023 [Accessed 2023 08 29]
529 https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf.
- 530 51. Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL. Adherence to palivizumab for
531 respiratory syncytial virus prevention in the Canadian registry of palivizumab. *Pediatr Infect Dis*
532 *J.* 2015;34(12):e290-7. doi: 10.1097/INF.0000000000000922.
- 533 52. Butt ML, Elliott L, Paes BA. Respiratory syncytial virus hospitalization and incurred
534 morbidities the season after prophylaxis. *Paediatr Child Health.* 2018;23(7):441-6. doi:
535 10.1093/pch/pxy046.
- 536 53. Statistics Canada. Table 13-10-0713-01 Infant deaths and mortality rates, by age group.

- 537 54. Statistics Canada. Table 13-10-0710-01 Mortality rates, by age group.
- 538 55. Hansen CL, Chaves SS, Demont C, Viboud C. Mortality associated with influenza and
539 respiratory syncytial virus in the US, 1999-2018. *JAMA Network Open*. 2022;5(2):e220527. doi:
540 10.1001/jama.289.2.179.
- 541 56. Hutton DW. Economic analysis of nirsevimab in pediatric populations. University of
542 Michigan; 2023 [Accessed 2023 08 29]
543 [https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/RSV-](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/RSV-Pediatric-02-Hutton-508.pdf)
544 [Pediatric-02-Hutton-508.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-23/RSV-Pediatric-02-Hutton-508.pdf)
- 545 57. Guertin JR, Feeny D, Tarride J-E. Age- and sex-specific Canadian utility norms, based on the
546 2013-2014 Canadian Community Health Survey. *CMAJ*. 2018;190(6):E155-E61. DOI:
547 <https://doi.org/10.1503/cmaj.170317>.
- 548 58. Statistics Canada. Canadian Vital Statistics, Death Database and Demography Division
549 (population estimates) [Accessed 2023 08 23]
550 <https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=3233>
- 551 59. Hodgson D, Atkins KE, Baguelin M, Panovska-Griffiths J, Thorrington D, van Hoek AJ,
552 Zhao H, Fragaszy E, Hayward AC, Pebody R. Estimates for quality of life loss due to respiratory
553 syncytial virus. *Influenza and other respiratory viruses*. *Influenza Other Respir Viruses*.
554 2020;14(1):19-27. doi: 10.1111/irv.12686.
- 555 60. Feltes TF, Simoes E. Palivizumab prophylaxis in haemodynamically significant congenital
556 heart disease. *Arch Dis Childhood*. 2005;90(8):875-7; doi. 10.1067/s0022-3476(03)00454-2
- 557 61. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA,
558 Szilagyi PG, Griffin MR, Williams JV, et al. Respiratory syncytial virus-associated

559 hospitalizations among children less than 24 months of age. *Pediatrics*. 2013;132(2):e341-8. doi:
 560 10.1542/peds.2013-0303.

561 62. The IMPact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus
 562 monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-
 563 risk infants. *Pediatrics*.1998;102(3 Pt 1):531-7.

564 63. Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM, Lynfield R, Bye E,
 565 Como-Sabetti K, Reingold A, et al. Estimated burden of community-onset respiratory syncytial
 566 virus-associated hospitalizations among children aged <2 years in the United States, 2014-15. *J*
 567 *Pediatric Infect Dis Soc*. 2020;9(5):587-95. doi: 10.1093/jpids/piz087.

568 64. Mitchell I, Defoy I, Grubb E. Burden of respiratory syncytial virus hospitalizations in
 569 Canada. *Can Respir J*. 2017:4521302. doi: 10.1155/2017/4521302.

570

571 **Table 1. Key model inputs**

| Parameter | Input | Range | Source |
|---|------------------|-------|---|
| Population | | | |
| Total annual births in Canada | 367,684 | - | Statistics Canada ⁽²⁰⁾ |
| Estimated number of PVZ-eligible infants | 6,711 (1.83%) | - | Calculations based on Statistics Canada ⁽²⁰⁾ and IQVIA ⁽⁴⁷⁾ |
| Estimated number of preterm infants (<37 wGA) | 22,497 (6.12%) | - | Calculation based on Statistics Canada ⁽²⁰⁾ |
| Estimated number of term infants (≥37 wGA) | 338,476 (92.06%) | - | Calculation based on Statistics Canada ⁽²⁰⁾ |
| Percent of PVZ-eligible infants in 2 nd season | 10% | - | Expert opinion |
| Seasonality of Disease | | | |
| April | 7.81% | - | Public Health Agency of Canada ⁽²¹⁾ |
| May | 3.32% | - | |
| June | 1.70% | - | |
| July | 0.58% | - | |
| August | 0.75% | - | |
| September | 2.33% | - | |
| October | 5.20% | - | |
| November | 6.76% | - | |
| December | 17.37% | - | |
| January | 21.40% | - | |
| February | 18.23% | - | |
| March | 14.56% | - | |
| Clinical Profile | | | |

| | | | |
|--|----------|-----------------|---|
| Nirsevimab duration of protection | 5 months | - | Griffin et al. (2020) ⁽¹⁴⁾ , Hammit et al. (2022) ⁽¹³⁾ , Muller et al. (2023) ⁽¹⁵⁾ , Drysdale et al. (2023) ⁽⁴⁸⁾ |
| Efficacy of nirsevimab among PVZ-eligible preterm infants ¹ | 51% | - | Andabaka et al. (2013) ⁽⁴⁹⁾ |
| Efficacy of nirsevimab among preterm infants | 86.2% | - | FDA (2023) ⁽⁵⁰⁾ |
| Efficacy of nirsevimab among term infants | 76.8% | - | Muller et al. (2023) ⁽¹⁵⁾ |
| Efficacy of PVZ | 51% | - | Andabaka et al. (2013) ⁽⁴⁹⁾ |
| First and second season coverage rate of PVZ among PVZ-eligible preterm infants | 81%, 10% | - | Chan et al. (2015) ⁽⁵¹⁾ , Butt et al. (2018) ⁽⁵²⁾ modified with expert opinion (second season coverage) |
| First and second season coverage rate of nirsevimab among PVZ-eligible preterm infants | 81%, 10% | - | Assumption based on palivizumab |
| First season coverage rate for nirsevimab among preterm and term infants ² | 30% | - | Statistics Canada ⁽³⁵⁾ |
| All-cause mortality among infants by age (per 1000) | | | |
| 0-5 months | 0.004 | | Statistics Canada ⁽⁵³⁾ |
| 6-11 months | 0.0003 | | Statistics Canada ⁽⁵³⁾ |
| 12-59 months | 0.0002 | | Statistics Canada ⁽⁵⁴⁾ |
| Overall risk of RSV-related mortality | | | |
| Preterm infants (including those PVZ-eligible) | 0.03% | | NACI ⁽¹⁸⁾ |
| Term infants | 0.0024% | | Hansen et al. (2022) ⁽⁵⁵⁾ |
| Lifetime QALY loss per RSV event | | | |
| Inpatient hospitalizations | 0.017 | 0.0101 – 0.0726 | Hutton et al. (2023) ⁽⁵⁶⁾ |
| ICU admission | 0.017 | 0.0101 – 0.0726 | |
| Mechanical ventilation (MV) | 0.017 | 0.0101 – 0.0726 | |
| Emergency room (ER) visit | 0.0134 | 0.0079 – 0.0455 | |
| Primary care (GP) visit | 0.0085 | 0.0049 – 0.0455 | |
| Parent/caregiver QALY loss | 0.005 | | |
| Lifetime QALY loss with Premature Death | | | |
| PVZ-eligible, preterm, and term infants | 41.697 | - | Calculation based on Guertin et al. (2018) ⁽⁵⁷⁾ , Statistics Canada ⁽⁵⁸⁾ , and Hodgson et al. (2020) ⁽⁵⁹⁾ |
| Discount rate | 1.5% | - | CADTH ⁽²⁹⁾ |

572 ¹PVZ refers to palivizumab; In the absence of published evidence, we assumed nirsevimab was equal in efficacy to
573 palivizumab

574 ²Conservative assumption that first season coverage of nirsevimab among healthy preterm and term infants would
575 mirror influenza vaccine coverage among infant group

576

577 **Caption:** Table 1 is a comprehensive list of all key model inputs, including population
578 assumptions, risks associated with seasonality of RSV, clinical profiles of nirsevimab and
579 palivizumab, mortality rates and lifetime QALY losses related to RSV.

580 **Table 2. Health-related inputs**

| Inpatient hospitalization | | | | |
|--|-----------------------------|------------------------|---------------------|--|
| Age at time of infection (months) | PVZ-eligible infants | Preterm infants | Term Infants | Source |
| 0 | 13.18% | 3.32% | 1.89% | Feltes et al. (2015) ⁽⁶⁰⁾ Hall et al. (2013) ⁽⁶¹⁾ IMPACT RSV Study Group (2018) ⁽⁶²⁾ McLaurin et al. (2016) ⁽²⁸⁾ Schanzer et al. (2018) ⁽⁵⁾ |
| 1 | 25.28% | 6.37% | 3.63% | |
| 2 | 13.96% | 3.52% | 2.00% | |
| 3 | 10.05% | 2.53% | 1.44% | |
| 4 | 8.69% | 2.19% | 1.25% | |
| 5 | 4.68% | 1.18% | 0.67% | |
| 6 | 4.00% | 1.01% | 0.57% | |
| 7 | 5.47% | 1.38% | 0.78% | |
| 8 | 3.32% | 0.84% | 0.48% | |
| 9 | 3.71% | 0.93% | 0.53% | |
| 10 | 3.61% | 0.91% | 0.52% | |
| 11 | 2.83% | 0.71% | 0.41% | |
| 12-24 | 2.50% | 0.59% | 0.20% | |
| 25-36 | 2.50% | 0.59% | 0.20% | |
| Intensive Care Unit (ICU) | | | | |
| 0 | 43.36% | 60.35% | 18.81% | Arriola et al. (2020) ⁽⁶³⁾ Mitchell et al. (2017) ⁽⁶⁴⁾ |
| 1 | 43.36% | 60.35% | 18.81% | |
| 2 | 43.36% | 60.35% | 18.81% | |
| 3 | 19.66% | 15.43% | 13.95% | |
| 4 | 19.66% | 15.43% | 13.95% | |
| 5 | 19.66% | 15.43% | 13.95% | |
| 6 | 11.42% | 9.28% | 10.31% | |
| 7 | 11.42% | 9.28% | 10.31% | |
| 8 | 11.42% | 9.28% | 10.31% | |
| 9 | 11.42% | 9.28% | 10.31% | |
| 10 | 11.42% | 9.28% | 10.31% | |
| 11 | 11.42% | 9.28% | 10.31% | |
| 12-24 | 18.67% | 31.26% | 10.92% | |
| 25-36 | 18.67% | 31.26% | 10.92% | |
| Mechanical Ventilation (MV) | | | | |
| 0 | 14.62% | 22.20% | 8.20% | Arriola et al. (2020) ⁽⁶³⁾ Buchan et al. (2019) ⁽²⁷⁾ |
| 1 | 14.62% | 22.20% | 8.20% | |
| 2 | 14.62% | 22.20% | 8.20% | |
| 3 | 5.69% | 6.80% | 1.82% | |
| 4 | 5.69% | 6.80% | 1.82% | |
| 5 | 5.69% | 6.80% | 1.82% | |
| 6 | 5.69% | 4.72% | 1.82% | |
| 7 | 5.69% | 4.72% | 1.82% | |
| 8 | 5.69% | 4.72% | 1.82% | |
| 9 | 5.69% | 4.72% | 1.82% | |
| 10 | 5.69% | 4.72% | 1.82% | |
| 11 | 5.69% | 4.72% | 1.82% | |
| 12-24 | 1.37% | 1.13% | 2.73% | |

| | | | | |
|----------------------------|--------|--------|--------|---|
| 25-30 | 1.37% | 1.13% | 2.73% | |
| Emergency Room (ER) | | | | |
| 0 | 1.96% | 1.96% | 1.96% | Lively et al. (2019) ⁽²³⁾ |
| 1 | 6.42% | 6.42% | 6.42% | |
| 2 | 7.24% | 7.24% | 7.24% | |
| 3 | 10.52% | 10.52% | 10.52% | |
| 4 | 11.60% | 11.60% | 11.60% | |
| 5 | 7.13% | 7.13% | 7.13% | |
| 6 | 8.18% | 8.18% | 8.18% | |
| 7 | 5.61% | 5.61% | 5.61% | |
| 8 | 5.56% | 5.56% | 5.56% | |
| 9 | 5.56% | 5.56% | 5.56% | |
| 10 | 4.04% | 4.04% | 4.04% | |
| 11 | 5.56% | 5.56% | 5.56% | |
| 12-24 | 5.30% | 5.30% | 5.30% | |
| 25-36 | 5.30% | 5.30% | 5.30% | |
| Primary Care (GP) | | | | |
| 0 | 8.52% | 8.52% | 8.52% | Lively et al. (2019) ⁽²³⁾ |
| 1 | 18.79% | 18.79% | 18.79% | |
| 2 | 23.42% | 23.42% | 23.42% | |
| 3 | 23.26% | 23.26% | 23.26% | |
| 4 | 26.50% | 26.50% | 26.50% | |
| 5 | 28.92% | 28.92% | 28.92% | |
| 6 | 26.47% | 26.47% | 26.47% | |
| 7 | 20.72% | 20.72% | 20.72% | |
| 8 | 27.78% | 27.78% | 27.78% | |
| 9 | 22.72% | 22.72% | 22.72% | |
| 10 | 24.17% | 24.17% | 24.17% | |
| 11 | 25.81% | 25.81% | 25.81% | |
| 12-24 | 18.03% | 18.03% | 18.03% | |
| 25-36 | 18.03% | 18.03% | 18.03% | |

581 Abbreviation PVZ: palivizumab

582 **Caption:** Health-related inputs for RSV are presented in Table 2 by wGA and infant category
583 risk for this disease.

584

585

586

587

588

589

590 **Table 3. Cost-related inputs**

| Direct Costs¹ | | | | | |
|--|-----------------------------|-------------------------------------|------------------------|---------------------|--|
| Health Outcomes | Scenarios | Average cost per event (CAD) | | | Source¹ |
| | | PVZ-eligible infants | Preterm infants | Term infants | |
| ER visits | All scenarios | \$836 | | | Weighted average costs based on Thampi et al. (2021) ⁽²⁶⁾ and Papenburg et al. (2020) ⁽²⁵⁾ |
| Primary care (GP) visits | All scenarios | \$94 | | | Papenburg et al. (2020) ⁽²⁵⁾ |
| Direct non-medical costs per inpatient hospitalization | All scenarios | \$652 | \$652 | \$220 | Papenburg et al. (2020) ⁽²⁵⁾ |
| Inpatient hospitalization | S ₀ ² | \$24,310 | \$11,380 | \$8,134 | Rafferty et al. (2022) ⁽²⁴⁾ |
| ICU admission | | \$48,301 | \$27,661 | \$21,238 | Thampi et al. (2021) ⁽²⁶⁾ |
| Mechanical ventilation | | \$130,943 | \$98,165 | \$40,601 | Buchan et al. (2019) ⁽²⁷⁾ Papenburg et al. (2020) ⁽²⁵⁾ |
| Inpatient hospitalization | S1a ² | \$25,918 | \$8,374 | \$5,968 | Rafferty et al. (2022) ⁽²⁴⁾ |
| ICU admission | | \$54,693 | \$24,381 | \$23,326 | |
| Mechanical ventilation | | \$89,667 | \$39,251 | \$49,039 | |
| Inpatient hospitalization | S1b ² | \$52,333 | \$16,908 | \$12,050 | Rafferty et al. (2022) ⁽²⁴⁾ |
| ICU admission | | \$110,434 | \$49,229 | \$47,100 | |
| Mechanical ventilation | | \$181,052 | \$79,254 | \$99,018 | |
| Inpatient hospitalization | S2 | \$25,529 | \$13,848 | \$9,462 | Thampi et al. (2021) ⁽²⁶⁾ |
| ICU admission | | \$25,529 | \$13,848 | \$9,462 | |
| Mechanical ventilation | | \$25,529 | \$13,848 | \$9,462 | |
| Inpatient hospitalization | S3 | \$9,268 | \$9,268 | \$6,104 | Buchan et al. (2019) ⁽²⁷⁾ |
| ICU admission | | \$9,268 | \$9,268 | \$6,104 | |
| Mechanical ventilation | | \$9,268 | \$9,268 | \$6,104 | |
| Inpatient hospitalization | S4 | \$8,503 | \$8,503 | \$7,086 | Papenburg et al. (2020) ⁽²⁵⁾ |
| ICU admission | | \$41,581 | \$41,581 | \$20,196 | |

| | | | | | |
|--|---------------|-----------|-----------|---|---|
| Mechanical ventilation | | \$349,202 | \$349,202 | \$39,384 | |
| Cost of Prophylaxis | | | | | |
| PVZ | All scenarios | \$1,599 | | | NACI (2023) ⁽¹⁸⁾ |
| Indirect Costs | | | | | |
| Average hourly earnings of all employees | All scenarios | \$25.39 | | | Papenburg et al. (2020) ⁽²⁵⁾ |
| Number of hours per workday | All scenarios | 8 hours | | | Mitchell et al. (2017) ⁽⁶⁴⁾ |
| Lost days per RSV episode (Inpatient) | All scenarios | 5.35 days | 2.56 days | Mitchell et al. (2017) ⁽⁶⁴⁾ | |
| Lost days per RSV episode (Outpatient) | All scenarios | 1.30 days | 1.40 days | Papenburg et al. (2020) ⁽²⁵⁾ | |

591 Abbreviation PVZ: palivizumab

592 ¹All costs from each source were adjusted for inflation to 2023 based on the latest consumer price index
 593 (CPI)

594 ²S1, S1a, S1b costing matrix was modelled based on the cost distribution from McLaurin et al. (2016)²⁸
 595 For S1, the case-weighted midpoint (average) direct hospital costs (<365 days but >30 days) for infants
 596 <1 year of age was \$21,342 based on Rafferty et al. (2022). For S1a, the average case-weighted within 30
 597 day RSV-attributable cost was \$14,138 (6% CPI adjusted) for infants <1 year of age. For S1b, the average
 598 case-weighted within 365 day RSV-attributable cost was \$28,546 (6% CPI adjusted) for infants <1 year
 599 of age. For each scenario, the midpoint/average case-weighted costs were used to generate the costing
 600 matrix according to McLaurin et al. (2016)²⁸
 601

602

603 **Caption:** Table 3 displays the RSV-related healthcare resource costs utilized in the model,
 604 stratified by infant risk for RSV.

605 **Table 4. Scenario-based price per dose (\$CAD) of nirsevimab at various willingness-to-pay (WTP)**
 606 **thresholds**

| Costing Scenarios ¹ | Willingness-to-pay threshold (\$ CAD/QALY) | Implementation Scenarios | | | |
|--------------------------------|--|--|---|--|--|
| | | All-infants born in & out-season (BASE CASE) | PVZ-eligible & preterm born in & out-season | PVZ-eligible & preterm born in & out-season, term infants (0-3 months) in 1st season and term infants born in-season | PVZ-eligible & preterm born in & out-season, term infants born in-season |
| S₀ | 40,000 | \$ 692 | \$ 3,767 | \$ 874 | \$ 1,117 |
| S1a | | \$ 677 | \$ 3,678 | \$ 854 | \$ 1,092 |
| S1b | | \$ 769 | \$ 3,875 | \$ 974 | \$ 1,235 |
| S2 | | \$ 660 | \$ 3,618 | \$ 829 | \$ 1,052 |
| S3 | | \$ 634 | \$ 3,565 | \$ 795 | \$ 1,018 |
| S4 | | \$ 721 | \$ 4,100 | \$ 918 | \$ 1,187 |
| S₀ | 50,000 | \$ 726 | \$ 3,827 | \$ 908 | \$ 1,149 |
| S1a | | \$ 711 | \$ 3,738 | \$ 888 | \$ 1,124 |
| S1b | | \$ 803 | \$ 3,935 | \$ 1,008 | \$ 1,267 |
| S2 | | \$ 694 | \$ 3,678 | \$ 863 | \$ 1,088 |
| S3 | | \$ 667 | \$ 3,625 | \$ 829 | \$ 1,049 |
| S4 | | \$ 755 | \$ 4,160 | \$ 952 | \$ 1,218 |
| S₀ | 70,000 | \$ 793 | \$ 3,946 | \$ 976 | \$ 1,213 |
| S1a | | \$ 778 | \$ 3,857 | \$ 956 | \$ 1,187 |
| S1b | | \$ 870 | \$ 4,054 | \$ 1,075 | \$ 1,330 |
| S2 | | \$ 762 | \$ 3,797 | \$ 930 | \$ 1,152 |
| S3 | | \$ 735 | \$ 3,745 | \$ 897 | \$ 1,113 |
| S4 | | \$ 823 | \$ 4,279 | \$ 1,020 | \$ 1,282 |
| S₀ | 100,000 | \$ 894 | \$ 4,126 | \$ 1,077 | \$ 1,308 |
| S1a | | \$ 879 | \$ 4,036 | \$ 1,057 | \$ 1,283 |
| S1b | | \$ 971 | \$ 4,233 | \$ 1,177 | \$ 1,426 |
| S2 | | \$ 863 | \$ 3,976 | \$ 1,032 | \$ 1,247 |
| S3 | | \$ 836 | \$ 3,924 | \$ 998 | \$ 1,209 |
| S4 | | \$ 924 | \$ 4,459 | \$ 1,121 | \$ 1,378 |

607 Abbreviation PVZ: palivizumab

608 ¹S₀: costing scenario used in base case with average costs derived from S1a, S1b, S2, S3, and S4; S1a: costs derived
 609 from Rafferty et al. (2023) representing costs within 30 days post-RSV infection; S1b: costs derived from Rafferty
 610 et al. (2023) representing costs within 365 days post-RSV infection; S2: scenario based on costs derived from
 611 Thampi et al. (2020); S3: scenario based on costs derived from Buchan et al. (2019); S4: scenario based on costs
 612 derived from Papenberg et al. (2020)

613 **Caption:** Price per dose (PPD) at the four studied WTP thresholds are presented in Table 4, per
 614 costing scenario and implementation scenario.

615 **Table 5. Comparative clinical and cost outcomes between existing therapy and nirsevimab for all newborn**
 616 **infants (born within and outside the RSV season)**

| | Current available standard of care ¹ | | | Nirsevimab ² | | | Total Difference ³ |
|--|---|---------------------|----------------------|-------------------------|---------------------|----------------------|-------------------------------|
| | PVZ-eligible infants | Preterm infants | Term infants | PVZ-eligible infants | Preterm infants | Term infants | |
| Health outcomes | | | | | | | |
| Inpatient hospitalizations (including ICU and MV) | 514 | 564 | 4,460 | 501 | 472 | 3,753 | -812 |
| ICU | 178 | 271 | 887 | 172 | 221 | 736 | -207 |
| MV | 40 | 66 | 216 | 39 | 53 | 179 | -51 |
| ER visits | 607 | 2,460 | 37,018 | 598 | 2,178 | 33,238 | -4,071 |
| GP visits | 2,118 | 8,518 | 128,164 | 2,095 | 7,592 | 115,750 | -13,363 |
| Inpatient deaths | 1 | 7 | 8 | 1 | 5 | 7 | -3 |
| Total health outcomes | 3,240 | 11,549 | 169,650 | 3,195 | 10,247 | 152,748 | -18,249 |
| Cost outcomes based on S₀ (average of all scenarios)³ | | | | | | | |
| Inpatient hospitalizations | \$8,133,343 | \$3,318,949 | \$28,984,272 | \$7,957,524 | \$2,835,394 | \$24,457,073 | -\$5,186,573 |
| ICU | \$6,615,125 | \$5,654,181 | \$14,203,343 | \$6,402,562 | \$4,650,320 | \$11,802,385 | -\$3,617,382 |
| MV | \$5,277,781 | \$6,515,735 | \$8,777,694 | \$5,090,006 | \$5,156,856 | \$7,240,593 | -\$3,083,755 |
| ER visits | \$503,259 | \$2,041,588 | \$30,548,015 | \$495,614 | \$1,805,919 | \$27,406,257 | -\$3,385,072 |
| GP visits | \$197,626 | \$795,965 | \$11,975,770 | \$195,458 | \$708,801 | \$10,807,350 | -\$1,257,752 |
| Direct non-medical costs per inpatient hospitalization | \$333,530 | \$366,501 | \$980,258 | \$325,015 | \$306,143 | \$824,352 | -\$224,779 |
| Total direct costs | \$21,060,664 | \$18,692,920 | \$95,469,351 | \$20,466,179 | \$15,463,432 | \$82,538,009 | -\$16,755,315 |
| Total indirect costs (excluding mortality) | \$1,269,837 | \$3,489,878 | \$48,957,742 | \$1,247,136 | \$3,070,157 | \$43,983,581 | -\$5,416,583 |
| Cost of inpatient death | \$7,431,138 | \$27,984,473 | \$33,683,455 | \$7,382,997 | \$26,003,892 | \$31,559,497 | -\$4,152,680 |
| Total Cost | \$29,761,639 | \$50,167,271 | \$178,110,548 | \$29,096,312 | \$44,537,481 | \$158,081,087 | -\$26,324,578 |

617 Abbreviation PVZ: palivizumab

618 ¹Current available standard of care is palivizumab, which is only offered, under strict criteria, to high-risk preterm
 619 infants who meet the age, comorbidity, seasonal, and/or geographic community for prophylaxis

620 ²In the base case scenario, nirsevimab is offered to all infants entering the RSV season born within or outside the RSV
 621 season

622 ³The base case scenario represents a wide spectrum of short-term and long-term costs across Canada (i.e. Alberta,
 623 Ontario, Quebec) specific to RSV-related hospitalization among infants.

624
 625
 626 **Caption:** In Table 5, the base case scenario (nirsevimab is offered to all infants entering
 627 the RSV season born within or outside the RSV season) is compared to the standard of
 628 care (palivizumab is offered to a select segment of high-risk preterm infants). Clinical
 629 and cost outcomes are presented.

630 **Figure 1. Modification formula for health-related inputs**

631
$$HI_{i,j} = \alpha \left(\frac{X_i}{\bar{X}_i} \right) * \left(\frac{X_i}{Z_i} \right)$$

632
633 *Let X = palivizumab – eligible infants; Y = preterm infants;*
634 *Z = term infants (point of reference)*

635
636 *HI_{i,j}: Canadian health input (e. g. inpatient hospitalization) for infant subgroup i and*
637 *age at time of infection j*

638 *α: Canadian modification value*

639 *X_i: Infant subgroup X (e. g. palivizumab – eligible infants) for age at time of infection i*

640 *\bar{X} : Average % of health input for infant subgroup X (e. g. palivizumab – eligible infants)*

641 *Z_i: Point of reference infant subgroup (i. e. term infants) for age at time of infection i*

642
643

644 **Figure 2. Modification formula for cost-related inputs [scenarios S1a, S1b based on Rafferty et al. (2023)]**

645
$$\text{Modifier } M = \frac{\sum \theta_{ij} \mu}{\sum_{ij} X_{ij} Y_{ij}}$$

646
$$\text{Cost Input}_{ij} = M * Y_{ij}$$

647 *i: subgroup (i. e. high – risk palivizumab – eligible, preterm, term)*

648 *j: health outcome (i. e. inpatient hospitalization, ICU, mechanical ventilation)*

649 *X: total number of in – season and out – season cases generated by the static model*

650 *Y: multiplier (reference) values based on the US costing distribution matrix*

651 *θ: Case counts of healthcare utilization*

652 *μ: Average, median, or midpoint values derived from the Canadian literature*

653

654

655

656

657

658


659

660

661

662

663 **Figure 3. Model structure**




664 The population includes infants less than two years of age, and it is divided into three subgroups to account for the
 665 differential individual risks of lower respiratory tract disease (LRTDs) and for the groups assessed in the nirsevimab
 666 clinical trials: Palivizumab-eligible infants, Preterm infants, and Late Preterm or Term infants. Infants experience
 667 different health events and require use of medical resources such as primary care (PC) and emergency room (ER)
 668 visits as well as hospitalizations. During the inpatient health state, infants might be in standard pediatric ward, admitted
 669 in intensive care unit (ICU) and requiring mechanical ventilation (MV). Non-medically events as referred to in this
 670 figure (in grey) are modelled in a scenario analysis, as well as all-cause LRTD hospitalizations, and complications
 671 following an RSV related hospitalization.

672 Abbreviations: ER = emergency room; ICU = intensive care unit; LRTD = lower respiratory tract disease; MV =
 673 mechanical ventilation; PC = primary care; RSV = respiratory syncytial virus; wGA = week of gestational age.

674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686

687 **Figure 4. Deterministic sensitivity analysis for price per dose (PPD)**



Abbreviations PPD: price per dose; DSA: deterministic sensitivity analysis

691 **Figure Captions**

692 Figure 1 Caption: The formula in Figure 1 was constructed to utilize average Canadian values
 693 and generate data points specific to health outcome, age of infection, and sub-group of interest,
 694 assuming a similar distribution of cases to the United States.

695 Figure 2 Caption: The formula in Figure 2 was constructed to utilize existing aggregate Canadian
 696 costs and generate specific outcome and sub-group specific costing data for RSV-related
 697 hospitalization, ICU admission, and mechanical ventilation, assuming a similar distribution of
 698 costs to the United States.

699 Figure 3 Caption: Figure 3 provides a visual illustration of the static model with the
 700 corresponding subgroups, health outcomes, and timeframe of interest.

701 Figure 4 Caption: The DSA was executed for all scenarios. Since each scenario only applies
 702 variations in the costing matrix, providing one DSA (base case) was considered appropriate to
 703 understand how each parameter affects the price per dose. Figure 3 was provided to illustrate the
 704 base case scenario for all infants within and outside the RSV season at the \$40,000 cost per
 705 QALY threshold.